<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="205597">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00412360</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN0501</org_study_id>
    <secondary_id>2U01HL069294</secondary_id>
    <secondary_id>5U24CA076518</secondary_id>
    <nct_id>NCT00412360</nct_id>
    <nct_alias>NCT00429598</nct_alias>
  </id_info>
  <brief_title>Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)</brief_title>
  <official_title>Multi-center, Open Label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia (BMT CTN #0501)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase III, randomized, open-label, multi-center, prospective study of single
      umbilical cord blood (UCB) transplantation versus double UCB transplantation in pediatric
      patients with hematologic malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      In nearly every large single center or registry analysis of outcomes after UCB
      transplantation, cell dose is identified as an important factor influencing the incidence
      and rate of hematopoietic recovery, risk of transplant-related mortality, and probability of
      survival. Pilot data suggest that infusion of two partially human leukocyte antigen
      (HLA)-matched UCB units, which always augments the graft cell dose, is safe and may improve
      neutrophil recovery and survival. To determine whether the infusion of two UCB units
      enhances survival, a multi-center, open-label, randomized trial is proposed. As adequate
      single UCB units can be identified for more than 80% of pediatric recipients (in contrast to
      less than 30% for adults), this study will be open only to pediatric patients. The
      population will be restricted to patients with high-risk hematologic malignancy, the most
      common indication of UCB transplantation in children.

      DESIGN NARRATIVE:

      Participants will include patients 1 to 21 years of age with a diagnosis of hematological
      malignancy and with two partially HLA-matched UCB units. Units must be HLA-matched at 3 of 6
      HLA-A and B (intermediate resolution molecular typing) and DRB1 (high resolution molecular
      typing) with each other and 4 of 6 with the recipient. Two appropriately HLA-matched units
      must be available such that one unit delivers a pre-cryopreserved, nucleated cell dose of at
      least 2.5 x 10^7 per kilogram and the second unit delivers at least 1.5 x 10^7 per kilogram.

      Patients will be randomized no more than 14 days prior to initiation of conditioning. UCB
      units will be shipped prior to initiation of conditioning.

      The preparative regimen will consist of the following:

        -  Fludarabine: 25 mg/m2/day IV on Days -10, -9, and -8.

        -  Total Body Irradiation (TBI): 165 cGy twice daily on Days -7, -6, -5, and -4.

        -  Cyclophosphamide: 60 mg/kg/day x 2 on Days -3 and -2.

        -  Day 0 will be the day of the UCB transplant. The Graft-vs-Host-Disease (GVHD)
           prophylaxis regimen will be mycophenolate mofetil (MMF) 15 mg/kg IV BID on Day -3 to
           Day + 45 and cyclosporine A (CSA) to maintain level 200-400 ng/mL beginning on Day -3.

      Patients will be followed for at least 24 months post-transplant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Year 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>Year 1</time_frame>
    <description>Disease-free survival is defined as the minimum time interval of the times to relapse/recurrence, to death or to last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil Engraftment</measure>
    <time_frame>Day 180</time_frame>
    <description>Neutrophil engraftment is defined as achieving an ANC â‰¥ 500/mm3 for three consecutive measurements on different days. The first of the three days will be designated the day of neutrophil engraftment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Graft-versus-host Disease (GVHD)</measure>
    <time_frame>Day 100</time_frame>
    <description>Incidences of grade II - IV and III - IV acute GVHD at Day 100 will be graded according to the BMT CTN Manual of Procedures (MOP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD</measure>
    <time_frame>Year 1</time_frame>
    <description>Incidences of chronic GVHD will be scored according to the BMT CTN MOP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related Mortality</measure>
    <time_frame>Year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>Year 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>Year 1</time_frame>
    <description>Testing for recurrent malignancy in the blood, marrow or other sites will be used to assess relapse after transplantation. For the purpose of this study, relapse is defined by either morphological or cytogenetic evidence of AML, ALL, CML, or MDS consistent with pre-transplant features.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Engraftment</measure>
    <time_frame>Day 180</time_frame>
    <description>Platelet engraftment to 50,000/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment Syndrome</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism</measure>
    <time_frame>28, 42, 60, 180, 365 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution</measure>
    <time_frame>100 days, 6 months, 1 and 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Natural Killer Cell Lymphoblastic Leukemia/Lymphoma</condition>
  <arm_group>
    <arm_group_label>Single Cord Blood Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unrelated donor, single umbilical cord blood unit transplant; conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Cord Blood Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unrelated donor, double umbilical cord blood unit transplant; Conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Single Umbilical Cord Blood Unit Transplant</intervention_name>
    <description>Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF</description>
    <arm_group_label>Single Cord Blood Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Double Umbilical Cord Blood Unit Transplant</intervention_name>
    <description>Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF</description>
    <arm_group_label>Double Cord Blood Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.</description>
    <arm_group_label>Single Cord Blood Transplant</arm_group_label>
    <arm_group_label>Double Cord Blood Transplant</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.</description>
    <arm_group_label>Single Cord Blood Transplant</arm_group_label>
    <arm_group_label>Double Cord Blood Transplant</arm_group_label>
    <other_name>CytoxanÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.</description>
    <arm_group_label>Single Cord Blood Transplant</arm_group_label>
    <arm_group_label>Double Cord Blood Transplant</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine A</intervention_name>
    <description>CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.</description>
    <arm_group_label>Single Cord Blood Transplant</arm_group_label>
    <arm_group_label>Double Cord Blood Transplant</arm_group_label>
    <other_name>CSA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>MMF will be given at a dose of 1 gram IV q 8 hours if &gt; 50 kg or 15 mg/kg IV q 8 hours if &lt; 50 kg beginning the morning of Day -3.</description>
    <arm_group_label>Single Cord Blood Transplant</arm_group_label>
    <arm_group_label>Double Cord Blood Transplant</arm_group_label>
    <other_name>MMF, CellceptÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Two partially HLA-matched UCB units. Units must be HLA-matched minimally at 4 of 6
             HLA-A and B (at intermediate resolution by molecular typing) and DRB1 (at high
             resolution by molecular typing) loci with the patient, and the units must be
             HLA-matched at 3 of 6 HLA- A, B, DRB1 loci with each other (using same resolution of
             molecular typing as indicated above). Two appropriately HLA-matched units must be
             available such that one unit delivers a pre-cryopreserved nucleated cell dose of at
             least 2.5 x 10^7 per kilogram and the second unit at least 1.5 x 10^7 per kilogram.

          -  Acute myelogenous leukemia (AML) at the following stages:

               1. High risk first complete remission (CR1), defined as the following:

                    -  Having preceding myelodysplasia (MDS)

                    -  High risk cytogenetics (high risk cytogenetics: del (5q) -5, -7, abn (3q),
                       t (6;9) complex karyotype [at least 5 abnormalities],)the presence of a
                       high FLT3 ITD-AR (&gt; 0.4)

                    -  Requiring more than 1 cycle of chemotherapy to obtain complete remission
                       (CR);

                    -  FAB M6

               2. Second or greater CR

               3. First relapse with less than 25% blasts in bone marrow

               4. Morphologic complete remission with incomplete blood count recovery

          -  Therapy-related AML for which prior malignancy has been in remission for at least 12
             months

          -  Acute lymphocytic leukemia (ALL) at the following stages:

               1. High risk first remission, defined as one of the following conditions:

                    -  Philadelphia chromosome-positive adult lymphoblastic leukemia (Ph+ ALL)

                    -  Mixed lineage leukemia (MLL) rearrangement with slow early response
                       (defined as having M2 [5-25% blasts] or M3 [more than 25% blasts on bone
                       marrow examination on Day 14 of induction therapy])

                    -  Hypodiploidy (less than 44 chromosomes or DNA index less than 0.81)

                    -  End of induction M3 bone marrow

                    -  End of induction M2 with M2-3 at Day 42

                    -  Evidence of minimal residual disease (MRD). If a patient's only high risk
                       criterion is MRD, approval by a protocol chair or protocol officer is
                       required for enrollment. For COG centers, this will only be for MRD greater
                       than 1 percent by flow MRD at the end of extended induction.

               2. High risk second remission, defined as one of the following conditions:

                    -  Philadelphia chromosome-positive adult lymphoblastic leukemia (Ph+ ALL)

                    -  Bone marrow relapse less than 36 months from induction

                    -  T-lineage relapse at any time

                    -  Very early isolated central nervous system (CNS) relapse (6 months from
                       diagnosis)

                    -  Slow reinduction (M2-3 at Day 28) after relapse at any time

                    -  Evidence of minimal residual disease (MRD). If a patient's only high risk
                       criterion is MRD, approval by a protocol chair or protocol officer is
                       required for enrollment. For COG centers, this will only be for MRD greater
                       than 1 percent by flow MRD at the end of extended induction.

               3. Any third or subsequent CR

          -  NK cell lymphoblastic leukemia in any CR

          -  Biphenotypic or undifferentiated leukemia in any CR or if in first relapse must have
             less than 25% blasts in bone marrow (BM)

          -  Myelodysplastic syndrome (MDS) at any stage

          -  Chronic myelogenous leukemia (CML) in chronic or accelerated phase

          -  All patients with evidence of CNS leukemia must be treated and be in CNS CR to be
             eligible for study.

          -  Patients 16 years old or older must have a Karnofsky score of at least 70% and
             patients younger than 16 years old must have a Lansky score of at least 70%.

          -  Patients with adequate physical function as measured by:

               1. Cardiac: Left ventricular ejection fraction greater than 40% or shortening
                  fraction greater than 26%

               2. Hepatic: Bilirubin no more than 2.5 mg/dL; alanine aminotransferase (ALT),
                  aspartate aminotransferase (AST), and alkaline phosphatase (ALP) no more than 5
                  times the upper limit of normal (ULN)

               3. Renal: Serum creatinine within normal range for age, or if serum creatinine is
                  outside normal range for age, then renal function (creatinine clearance or GFR)
                  greater than 70 mL/min/1.73 m^2

               4. Pulmonary: Diffusing capacity of the lung for carbon monoxide (DLCO), forced
                  expiratory volume in one second (FEV1), or forced vital capacity (FVC) greater
                  than 50% of predicted value (corrected for hemoglobin); if unable to perform
                  pulmonary function tests, then O2 saturation greater than 92% of room air

        Exclusion Criteria:

          -  Pregnant (Î²-positive human chorionic gonadotropin [HCG]) or breastfeeding

          -  Evidence of HIV infection or HIV positive serology

          -  Current uncontrolled bacterial, viral, or fungal infection (currently taking
             medication and progression of clinical symptoms)

          -  Autologous transplant less than 12 months prior to enrollment

          -  Prior autologous transplant for the disease for which the UCB transplant will be
             performed

          -  Prior allogeneic hematopoietic stem cell transplant

          -  Active malignancy other than the one for which the UCB transplant is being performed
             within 12 months of enrollment

          -  Inability to receive TBI

          -  Requirement of supplemental oxygen

          -  HLA-matched related donor able to donate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Horowitz, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD/Rady Childrens Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco (Peds)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine (Shands)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Childrens Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322-1062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville/Kosiar Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's of New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DFCI/Children's Hospital of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute/Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-7610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Childrens Medical Center</name>
      <address>
        <city>Forth Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah BMT/University of Utah Medical School</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virgina Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net</url>
    <description>Blood and Marrow Transplant Clinical Trials Network</description>
  </link>
  <link>
    <url>https://www.nmdp.org</url>
    <description>National Marrow Donor Program</description>
  </link>
  <results_reference>
    <citation>Wagner JE Jr, Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, Bunin N, Delaney C, Haut P, Margolis D, Peres E, Verneris MR, Walters M, Horowitz MM, Kurtzberg J; Blood and Marrow Transplant Clinical Trials Network.. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med. 2014 Oct 30;371(18):1685-94. doi: 10.1056/NEJMoa1405584.</citation>
    <PMID>25354103</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>June 27, 2016</lastchanged_date>
  <firstreceived_date>December 14, 2006</firstreceived_date>
  <firstreceived_results_date>August 28, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Double cord blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Vidarabine Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Findings were published in a manuscript.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single UCB Transplant</title>
          <description>Single Cord Blood Unit Transplantation: Unrelated donor, single cord blood unit</description>
        </group>
        <group group_id="P2">
          <title>Double UCB Transplant</title>
          <description>Double Cord Blood Unit Transplantation: Unrelated donor, double cord blood unit</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis based on intent-to-treat.</population>
      <group_list>
        <group group_id="B1">
          <title>Single UCB Transplant</title>
          <description>Single Umbilical Cord Blood Unit Transplantation</description>
        </group>
        <group group_id="B2">
          <title>Double UCB Transplant</title>
          <description>Double Umbilical Cord Blood Unit Transplantation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="113"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="224"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.4" spread="5.1"/>
                    <measurement group_id="B2" value="10.4" spread="5.1"/>
                    <measurement group_id="B3" value="10.4" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Acute Myelogenous Leukemia (AML)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Lymphoblastic Leukemia (ALL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Biphenotypic Leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Undifferentiated Leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myelodysplastic Syndrome (MDS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Myelogenous Leukemia (CML)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary/Therapy Related AML</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance-status Score</title>
          <description>Assesses patient self-perceived global quality of life and functioning (excellent, very good, good, fair, poor), where 100 equals perfect quality of life.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>100%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Recipient to First CBU HLA Match</title>
          <description>Data limited to transplanted patients only.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>3/6 HLA markers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4/6 HLA markers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/6 HLA markers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6/6 HLA markers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Minimum HLA Match Score</title>
          <description>Data limited to transplanted patients only. Minimum HLA match is defined as the minimum match score between the first unit/recipient, second unit/recipient, or first unit/second unit.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>3/6 HLA markers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4/6 HLA markers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/6 HLA markers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6/6 HLA markers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight at Infusion</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.6" spread="20.2"/>
                    <measurement group_id="B2" value="38.7" spread="19.2"/>
                    <measurement group_id="B3" value="39.15" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Recipient CMV Status</title>
          <description>Data limited to transplanted patients only.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconclusive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <time_frame>Year 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single UCB Transplant</title>
            <description>Single Umbilical Cord Blood Unit Transplantation</description>
          </group>
          <group group_id="O2">
            <title>Double UCB Transplant</title>
            <description>Double Umbilical Cord Blood Unit Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.6" lower_limit="63.3" upper_limit="79.8"/>
                    <measurement group_id="O2" value="65.4" lower_limit="55.8" upper_limit="73.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival</title>
        <description>Disease-free survival is defined as the minimum time interval of the times to relapse/recurrence, to death or to last follow-up.</description>
        <time_frame>Year 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single UCB Transplant</title>
            <description>Single Umbilical Cord Blood Unit Transplantation</description>
          </group>
          <group group_id="O2">
            <title>Double UCB Transplant</title>
            <description>Double Umbilical Cord Blood Unit Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>Disease-free survival is defined as the minimum time interval of the times to relapse/recurrence, to death or to last follow-up.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" lower_limit="59.6" upper_limit="76.7"/>
                    <measurement group_id="O2" value="62.7" lower_limit="53.0" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutrophil Engraftment</title>
        <description>Neutrophil engraftment is defined as achieving an ANC â‰¥ 500/mm3 for three consecutive measurements on different days. The first of the three days will be designated the day of neutrophil engraftment.</description>
        <time_frame>Day 180</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single UCB Transplant</title>
            <description>Single Umbilical Cord Blood Unit Transplantation</description>
          </group>
          <group group_id="O2">
            <title>Double UCB Transplant</title>
            <description>Double Umbilical Cord Blood Unit Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophil Engraftment</title>
          <description>Neutrophil engraftment is defined as achieving an ANC â‰¥ 500/mm3 for three consecutive measurements on different days. The first of the three days will be designated the day of neutrophil engraftment.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" lower_limit="83.4" upper_limit="95.2"/>
                    <measurement group_id="O2" value="88.0" lower_limit="81.7" upper_limit="94.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft-versus-host Disease (GVHD)</title>
        <description>Incidences of grade II â€“ IV and III â€“ IV acute GVHD at Day 100 will be graded according to the BMT CTN Manual of Procedures (MOP).</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single UCB Transplant</title>
            <description>Single Umbilical Cord Blood Unit Transplantation</description>
          </group>
          <group group_id="O2">
            <title>Double UCB Transplant</title>
            <description>Double Umbilical Cord Blood Unit Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft-versus-host Disease (GVHD)</title>
          <description>Incidences of grade II â€“ IV and III â€“ IV acute GVHD at Day 100 will be graded according to the BMT CTN Manual of Procedures (MOP).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic GVHD</title>
        <description>Incidences of chronic GVHD will be scored according to the BMT CTN MOP.</description>
        <time_frame>Year 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single UCB Transplant</title>
            <description>Single Umbilical Cord Blood Unit Transplantation</description>
          </group>
          <group group_id="O2">
            <title>Double UCB Transplant</title>
            <description>Double Umbilical Cord Blood Unit Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic GVHD</title>
          <description>Incidences of chronic GVHD will be scored according to the BMT CTN MOP.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chronic GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" lower_limit="21.8" upper_limit="39.0"/>
                    <measurement group_id="O2" value="31.5" lower_limit="22.7" upper_limit="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extensive Chronic GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="3.6" upper_limit="14.2"/>
                    <measurement group_id="O2" value="14.8" lower_limit="8.1" upper_limit="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-related Mortality</title>
        <time_frame>Year 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single UCB Transplant</title>
            <description>Single Umbilical Cord Blood Unit Transplantation</description>
          </group>
          <group group_id="O2">
            <title>Double UCB Transplant</title>
            <description>Double Umbilical Cord Blood Unit Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Mortality</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="11.4" upper_limit="26.0"/>
                    <measurement group_id="O2" value="22.2" lower_limit="14.3" upper_limit="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infections</title>
        <time_frame>Year 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single UCB Transplant</title>
            <description>Single Umbilical Cord Blood Unit Transplantation</description>
          </group>
          <group group_id="O2">
            <title>Double UCB Transplant</title>
            <description>Double Umbilical Cord Blood Unit Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Infections</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total number of infections</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
                <count group_id="O2" value="520"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-10 Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 Infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse</title>
        <description>Testing for recurrent malignancy in the blood, marrow or other sites will be used to assess relapse after transplantation. For the purpose of this study, relapse is defined by either morphological or cytogenetic evidence of AML, ALL, CML, or MDS consistent with pre-transplant features.</description>
        <time_frame>Year 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single UCB Transplant</title>
            <description>Single Umbilical Cord Blood Unit Transplantation</description>
          </group>
          <group group_id="O2">
            <title>Double UCB Transplant</title>
            <description>Double Umbilical Cord Blood Unit Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse</title>
          <description>Testing for recurrent malignancy in the blood, marrow or other sites will be used to assess relapse after transplantation. For the purpose of this study, relapse is defined by either morphological or cytogenetic evidence of AML, ALL, CML, or MDS consistent with pre-transplant features.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="5.6" upper_limit="17.6"/>
                    <measurement group_id="O2" value="13.9" lower_limit="7.3" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Engraftment</title>
        <description>Platelet engraftment to 50,000/mL</description>
        <time_frame>Day 180</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single UCB Transplant</title>
            <description>Single Umbilical Cord Blood Unit Transplantation</description>
          </group>
          <group group_id="O2">
            <title>Double UCB Transplant</title>
            <description>Double Umbilical Cord Blood Unit Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Engraftment</title>
          <description>Platelet engraftment to 50,000/mL</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" lower_limit="68.3" upper_limit="84.5"/>
                    <measurement group_id="O2" value="65.1" lower_limit="55.9" upper_limit="74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Engraftment Syndrome</title>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single UCB Transplant</title>
            <description>Single Umbilical Cord Blood Unit Transplantation</description>
          </group>
          <group group_id="O2">
            <title>Double UCB Transplant</title>
            <description>Double Umbilical Cord Blood Unit Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Engraftment Syndrome</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Engraftment Syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Engraftment Syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chimerism</title>
        <time_frame>28, 42, 60, 180, 365 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution</title>
        <time_frame>100 days, 6 months, 1 and 2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years post-transplant</time_frame>
      <desc>Serious Adverse Events (AE) are defined as events associated with death, life-threatening event, disability, congenital anomaly, required intervention to prevent permanent impairment or damage, hospitalization or other serious adverse event. Only unexpected grades 3-5 adverse events were required to be reported through the AE system per protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Single UCB Transplant</title>
          <description>Single Umbilical Cord Blood Unit Transplantation</description>
        </group>
        <group group_id="E2">
          <title>Double UCB Transplant</title>
          <description>Double Umbilical Cord Blood Unit Transplantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolytic anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Respiratory failure from Pneumonia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute intracranial Hemorrage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Seizure/aspiration Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pulmonary Hemorrage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Aspiration Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Mendizabal</name_or_title>
      <organization>The EMMES Corporation</organization>
      <phone>301-251-1161</phone>
      <email>amendizabal@EMMES.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
